Antibody-drug conjugate

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

Retrieved on: 
Tuesday, May 16, 2023
Area studies, Partnership, Freedom, Astellas Pharma, Backbone, Sony, Enzyme, Type, Research, Cell, Solubility, Aggregation, Patient, OBI Pharma, Inc., Drug discovery, Conjugation, Biology, ADC, DAR, Antibody-drug conjugate, TSE, Fine chemical, Pharmaceutical industry

TOKYO, May 16, 2023 /PRNewswire/ -- Sony Corporation (President and CEO: Kimio Maki, "Sony") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC)*1 platform in oncology based on Sony's unique polymeric material, "KIRAVIA™*2 Backbone*3." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which conjugates antibodies and drugs, is considered to be a key to development of a better-performing ADC. This collaborative research leverages the flexibility in design and resulting properties such as high capacity and solubility of KIRAVIA Backbone as a linker of ADC, to effectively deliver anti-cancer drugs to targeted cells in a stable manner, aiming to further enhance therapeutic efficacy by achieving high Drug-to-Antibody Ratio (DAR) etc.

Key Points: 
  • " ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells.
  • The technology to create linkers which conjugates antibodies and drugs, is considered to be a key to development of a better-performing ADC.
  • The two companies jointly began exploratory research of new linker technology aimed at creating a new ADC platform in July 2022, and the expected profile was obtained in feasibility studies using human cancer cells.
  • Under this agreement, Sony and Astellas will jointly develop and optimize a new ADC platform using the KIRAVIA Backbone as a linker.

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Wednesday, May 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PTCL, Monalizumab, Abstract, CT, AACR, Antibody-drug conjugate, IO, Coeliac disease, American depositary receipt, Cancer, Acute lymphoblastic leukemia, American Association for Cancer Research, NK, Research, NSCLC, Lung cancer, AstraZeneca, Acute myeloid leukemia, ASCO, ATM, AML, American Society of Clinical Oncology, Patient, SS, CD123, Annual general meeting, Webcast, Sanofi, Nature Biotechnology, ADC, Poster, Mycosis fungoides, CRT, Society, IND, BCMA, Fine chemical, Pharmaceutical industry, Vaccine, Takeda, Innate Immunotherapeutics

Innate continues to see progress for lacutamab with final data from the TELLOMAK Phase 2 trial for both mycosis fungoides (MF) and Sézary syndrome (SS) expected in H2 2023.

Key Points: 
  • Innate continues to see progress for lacutamab with final data from the TELLOMAK Phase 2 trial for both mycosis fungoides (MF) and Sézary syndrome (SS) expected in H2 2023.
  • Cash, cash equivalents and financial assets of the Company amounted to €135.0 million as of March 31, 2023.
  • Cash, cash equivalents and financial assets as of March 31, 2023 do not include the $5.0 million payment to be received from Takeda.
  • Revenues for the first three months of 2023 amounted to €26.0 million (€2.6 million for the same period in 2022).

Leaders in Breast and Lung Cancer treatment join SystImmune Inc's Clinical Science Advisory Committee

Retrieved on: 
Wednesday, April 26, 2023
IDeA Networks of Biomedical Research Excellence, TNBC, Memorial Sloan Kettering Cancer Center, Triple-negative breast cancer, Therapy, SPORE, CDK, Cancer and Leukemia Group B, Belfer Center for Science and International Affairs, Survival, Cancer, Lung cancer, Woman, MMSC, Research, NSCLC, CMO, CALGB, Immunotherapy, Biomarker, Associate, Oncology, Harvard Medical School, CSAC, Patient, UCSF, Breast cancer, Division, Susan, EGFR, MSK, Biology, ADC, Haematopoietic system, Antibody-drug conjugate, George M. Low Center for Industrial Innovation, Disease, Dana–Farber Cancer Institute, Medical device, Birth control, Medical imaging, Sacituzumab govitecan, Medicine

Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.

Key Points: 
  • Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.
  • They have led high-profile clinical programs, including the development of Trodelvy (sacituzumab govitecan-hziy), the most recent drug approved for the treatment of triple-negative breast cancer (TNBC).
  • Their expertise will guide SystImmune in the advancement of its ADC pipeline into breast cancer.
  • Dr. Rugo is the director of UCSF's breast cancer clinical trials program and the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late-stage breast cancer.

EQS-News: Defence Therapeutics Inc.: DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY

Retrieved on: 
Monday, April 24, 2023
Vaccine, Defense, Patent, Antibody-drug conjugate, United States Patent and Trademark Office, Infection, ARM, Cancer, Breast, Messenger, Science, CD8, Cervical cancer, Antigen presentation, Melanoma, CD4, Therapy

Vancouver, BC, Canada, April 24, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates (“ADCs”), is pleased to announce the issuance of its US patent no.

Key Points: 
  • Vancouver, BC, Canada, April 24, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates (“ADCs”), is pleased to announce the issuance of its US patent no.
  • 11,612,651 by the United States Patent and Trademark Office (USPTO).
  • The US patent broadly covers Defence’s AccumTM-based vaccine enhancer technology platform as a powerful “drop-in” ingredient to boost immunogenicity and performance of virtually any cell-based or protein subunit vaccine, including both prophylactic and therapeutic vaccines in the fields of cancer and infectious diseases.
  • “The rapid granting of this broad patent by the USPTO is a testament to the innovative nature and quality of the underlying science behind Defence’s AccumTM technology.

EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023

Retrieved on: 
Saturday, April 15, 2023
Interim, State University of New York, ASH, Marketing, HPHA, SRC, Bank statement, Binghamton University, Clinical trial, Tax, Bone marrow, Cancer, State university system, FSE, Magenta, Research, EBIT, Patient safety, August Faller GmbH & Co. KG, Gesellschaft mit beschränkter Haftung, Amanitin, Malignancy, EUR, Patient, Antibody-drug conjugate, Immune system, MM, CFO, Depreciation, ADC, Spacecraft, R, Phase, Therapy, Death, Society, BCMA, Safety, Security (finance), Pharmaceutical industry, Generic drug, Lithium, ATAC

Ladenburg, Germany, 4 April 2023 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2023 (1 December 2022 – 28 February 2023) and the Group’s financial figures.

Key Points: 
  • Ladenburg, Germany, 4 April 2023 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2023 (1 December 2022 – 28 February 2023) and the Group’s financial figures.
  • The Heidelberg Pharma Group – as of the reporting date comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • Heidelberg Pharma will not host a conference call on this interim management statement.
  • The complete figures for the interim financial statements can be downloaded from http://www.heidelberg-pharma.com/ ”Press & Investors > Announcements > Financial Reports > Interim management statement on the first three months of 2023.

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Retrieved on: 
Monday, April 3, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Coeliac disease, ADC, Euronext Paris, Antibody-drug conjugate, IPH, Natural killer cell, IPHA, Takeda, Antibody, Vaccine, Innate Immunotherapeutics

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
  • Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies.
  • “We are thrilled to be working with Takeda, a company which has been very successful in developing new drugs across multiple therapeutic areas.
  • This agreement expands the application of Innate’s science beyond our oncology focus and demonstrates how our antibody engineering expertise can play a major role in developing Antibody Drug Conjugate formats.

Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards

Retrieved on: 
Tuesday, March 7, 2023
Partnership, ADC, Growth, Map, Business development, Mass spectrometry, Cancer, Therapy, Conjugation, Patient, SME, Antibody-drug conjugate, OBT, Senior, The Business, Fine chemical, Management, Operation, Thames Valley

Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody-Drug Conjugate (ADC)-based therapies, announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.

Key Points: 
  • Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody-Drug Conjugate (ADC)-based therapies, announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.
  • These awards celebrate the region's most active small and medium-sized enterprises (SMEs) that have grown significantly in the past year.
  • The ‘Tech Company of the Year’ award recognises exceptional use of technology to advance company objectives, improve communities and/or empower clients.
  • This company’s ground-breaking achievements make them a very worthy winner.”
    “We are honoured to have received these awards,” said Christian Rohlff, CEO at Oxford BioTherapeutics.

Immunome to Present at 13th Annual World ADC London Conference

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Genetics, Health, ADC, Protein, Therapy, Research, Antibody, Antibody-drug conjugate, Event, Cancer, Spacecraft, Fine chemical

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023.
  • World ADC London is Europe’s longest standing and definitive antibody-drug conjugate (ADC) event dedicated to maximizing the therapeutic window of ADCs.
  • Dr. Robinson will give a platform talk on Wednesday, March 15 discussing how Immunome’s Discovery Engine can highlight novel target classes which have relevance for multiple therapeutic modalities, including ADCs.
  • “Human memory B cells are able to record the targets that are classified as important attack points for antibodies across the course of tumor development.

Growth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing 2022

Retrieved on: 
Friday, March 3, 2023
Innovation system, Spacecraft, Tissue engineering, Health, POC, Nanomedicine, RNA, Genetic engineering, Gene editing, Automation, Synthetic biology, Regenerative medicine, Drug discovery, Wellness, Pain, Therapy, Antibody-drug conjugate, Scalability, Biomanufacturing, Biomarker, Vaccine, Pharmaceutical industry

DUBLIN, March 2, 2023 /PRNewswire/ -- The "Growth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 2, 2023 /PRNewswire/ -- The "Growth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing" report has been added to ResearchAndMarkets.com's offering.
  • It also covers few innovations around ADCs (antibody drug conjugates) and its different components which are paving the way for development of safer and longer acting ADCs.
  • In addition, advances in RNA therapeutics including small activating RNA and circular RNA based therapeutics and targeted delivery carriers have been covered.
  • Innovations in Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing
    Value Proposition of Precision Biosciences,
    Flexible, Scalable and Cost-efficient Peptide Based Linker Platform, Offering Highly Stable Antibody Drug Conjugates

Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors

Retrieved on: 
Thursday, February 23, 2023
Health, Infectious Diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Aston, Chemical engineering, Knowledge, Therapy, University, MBA, Spacecraft, MedImmune, Entrepreneurship, Growth, International Institute for Management Development, AstraZeneca, Engineering physics, Antibody-drug conjugate, Aston University, Vaccine, Jim May (chemical engineer), Pharmaceutical industry

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Chris Martin to its Board of Directors.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Chris Martin to its Board of Directors.
  • Dr. Martin brings with him over 20 years of experience in the pharmaceutical and biotech sector.
  • He is an accomplished company founder and director who has successfully brought technology from the lab to regulatory approval and global markets.
  • “We are deeply saddened by the loss of Dr. Mike Watson, who served on our Board of Directors with distinction.